Skip to content

Duvelisib

Copiktra (duvelisib) is a small molecule pharmaceutical. Duvelisib was first approved as Copiktra on 2018-09-24. It is used to treat b-cell chronic lymphocytic leukemia in the USA. It has been approved in Europe to treat b-cell chronic lymphocytic leukemia and follicular lymphoma. The pharmaceutical is active against phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform and phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform. In addition, it is known to target phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform and phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform. Copiktra's patents are valid until 2032-05-17 (FDA).
Trade Name Copiktra
Common Name Duvelisib
Indication b-cell chronic lymphocytic leukemia, follicular lymphoma
Drug Class Phosphatidylinositol 3-kinase inhibitors
Duvelisib
Get full access now